Biocon FY26 Annual Earnings Summary
4 quarters covered · ₹16,928 Cr revenue · ₹232 Cr PAT · 22.3% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Promise tracking available after 2+ quarters of coverage.
Risks flagged during the year
Net debt of $1.15 billion at Biocon Biologics continues to weigh on consolidated financials, though QIP and structured equity repayments are expected to reduce interest costs gradually.
Q2 FY26 · highFive players are already in the Denosumab market with five more in the pipeline, increasing competitive intensity.
Q1 FY26 · mediumOperating costs from three newly capitalized facilities (peptide, Vizag, Cranbury) are impacting generics EBITDA by ~INR 60 crore per quarter, with pressure expected to persist until utilization ramps up in H2.
Q1 FY26 · mediumAdalimumab in the U.S. remains a work in progress with pricing pressure and dominance of private labelers (Sandoz/CVS); market share gains uncertain.
Q1 FY26 · mediumHealth Canada has not approved any generic GLP-1; semaglutide approval may be delayed beyond best-case timeline of end-2026.
Q2 FY26 · mediumTop formularies like Optum Rx and Express Scripts have excluded aspart as a class, potentially limiting TAM for Kirsty.
Q2 FY26 · mediumMarket share and ASPs are inversely proportional; increased competition could erode pricing and margins.
Q2 FY26 · mediumFixed costs from three new facilities capitalized in FY25 continue to pressure generics margins.
Q3 FY26 · mediumCRDMO revenue declined 3% YoY due to challenges with one customer, and management acknowledged the pressure will take time to ease.
Q3 FY26 · mediumHealth Canada has not approved any generic GLP-1, including liraglutide, due to unclear regulatory requirements, delaying semaglutide launch.
Q3 FY26 · mediumNovo Nordisk's potential launch of a different formulation (e.g., oral) could impact generic GLP-1 market dynamics.
Q4 FY26 · mediumCompetitive pressure and ASP declines in medical benefit products could impact margins.
What changed through the year
Q1 FY26 · Generics double-digit revenue growth for FY26
Management expects strong double-digit revenue growth for the generics segment for the full fiscal year, driven by multiple product launches including liraglutide in Europe and the U.S.
Q1 FY26 · Liraglutide U.S. approval expected this fiscal
Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.
Q1 FY26 · Denosumab U.S. approval by end of calendar 2025
Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.
Q1 FY26 · Semaglutide filings in Q2 FY26 for emerging markets and Canada
Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.
Q2 FY26 · Biosimilar R&D spend at 7-9% of revenue
Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
Q2 FY26 · Generics R&D spend at 8-10% of revenue
Generics R&D spend is expected to be in the 8-10% range of segment revenue.
Q2 FY26 · Generics gross margin improvement in H2
Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.
Q2 FY26 · Syngene maintains FY26 annual guidance
Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.
Q3 FY26 · Annualized interest savings of ~₹300 crore from FY27
Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.
Q3 FY26 · Biosimilar EBITDA margin to be in mid-20s for full year FY26
Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.
Q3 FY26 · Capex to moderate to <$225 million and further decline
Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.
Q3 FY26 · Insulin drug product capacity to double in FY27
The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.
Q4 FY26 · Biosimilar revenue growth of 16% in FY26 on like-to-like basis
Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.
Q4 FY26 · EBITDA margin expansion of ~200bps in FY26 on like-to-like basis
Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.
Q4 FY26 · Net debt reduction to ~$1.1B from $1.5B in March 2025
Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.
Q4 FY26 · Aflibercept (Yesafili) launch in US in H2 FY27
Settlement with originator allows entry; management expects meaningful revenue contribution from H2.